These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15899739)

  • 1. Azacitidine-induced interstitial and alveolar fibrosis in a patient with myelodysplastic syndrome.
    Adams CD; Szumita PM; Baroletti SA; Lilly CM
    Pharmacotherapy; 2005 May; 25(5):765-8. PubMed ID: 15899739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine-induced pneumonitis in a patient with myelodysplastic syndrome: first case report in Japan.
    Hayashi M; Takayasu H; Tada M; Yamazaki Y; Tateno H; Tazawa S; Wakabayashi A; Iwasaki T; Tsuchiya Y; Yamashita J; Takeda N; Tomita S; Mori H; Kokubu F
    Intern Med; 2012; 51(17):2411-5. PubMed ID: 22975559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial lung disease associated with azacitidine use: a case report.
    Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR
    Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eosinophilic pneumonia associated with azacitidine in a patient with myelodysplastic syndrome.
    Nair GB; Charles M; Ogden L; Spiegler P
    Respir Care; 2012 Apr; 57(4):631-3. PubMed ID: 22005027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there an association between 5-azacitidine and ototoxicity?
    Malik A; Misbah S; Spaccavento C; Yudelman I
    J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
    [No Abstract]   [Full Text] [Related]  

  • 6. Azacitidine-associated Sweet's syndrome.
    Trickett HB; Cumpston A; Craig M
    Am J Health Syst Pharm; 2012 May; 69(10):869-71. PubMed ID: 22555082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine-associated hyperthermia and interstitial pneumonitis in a patient with myelodysplastic syndrome.
    Hueser CN; Patel AJ
    Pharmacotherapy; 2007 Dec; 27(12):1759-62. PubMed ID: 18041893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strongly suspicious hemolysis caused by azacitidine in a myelodysplastic syndrome patient.
    Ichikawa K; Aritaka N; Ogura K; Komatsu N; Hirano T
    Geriatr Gerontol Int; 2014 Oct; 14(4):1006-7. PubMed ID: 25327907
    [No Abstract]   [Full Text] [Related]  

  • 9. Azacitidine-associated acute interstitial pneumonitis.
    Kuroda J; Shimura Y; Mizutani S; Nagoshi H; Kiyota M; Chinen Y; Maegawa S; Kobayashi T; Matsumoto Y; Horiike S; Taniwaki M
    Intern Med; 2014; 53(11):1165-9. PubMed ID: 24881742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine.
    Infante MS; Muñoz C; Heras C; Foncillas MA; González I; Lucea I; Echavarria E; Aramendi T; Hernández JA
    Eur J Dermatol; 2015; 25(6):622-3. PubMed ID: 26552844
    [No Abstract]   [Full Text] [Related]  

  • 11. Neutrophilic panniculitis following azacitidine treatment for myelodysplastic syndromes.
    Kim IH; Youn JH; Shin SH; Yahng SA; Lee SE; Kwon JC; Lee DG; Park KS; Choi MH; Jung SE; Kim YJ
    Leuk Res; 2012 Jul; 36(7):e146-8. PubMed ID: 22483068
    [No Abstract]   [Full Text] [Related]  

  • 12. Glycemic dysregulation in a patient with type 2 diabetes treated with 5-azacitidine: a case report.
    Ponard A; Ferreira-Maldent N; Ertault M; Delain M; Amraoui K; Regina S; Jonville-Béra AP; Hérault O; Colombat P; Gyan E
    J Med Case Rep; 2018 Jul; 12(1):199. PubMed ID: 29966534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azacitidine: in myelodysplastic syndromes.
    Siddiqui MA; Scott LJ
    Drugs; 2005; 65(13):1781-9; discussion 1790-1. PubMed ID: 16114977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine and the beginnings of therapeutic epigenetic modulation.
    O'Dwyer K; Maslak P
    Expert Opin Pharmacother; 2008 Aug; 9(11):1981-6. PubMed ID: 18627335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.
    Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F
    Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine-associated pleuropericardial effusion in myelodysplastic syndrome: A case report.
    Goo K; Uy R; Roswarski J
    J Oncol Pharm Pract; 2019 Jul; 25(5):1248-1252. PubMed ID: 29933727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine.
    Gore SD; Jones C; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Nov; 5(11):891-2. PubMed ID: 17117522
    [No Abstract]   [Full Text] [Related]  

  • 19. Recurrence of abdominal large-vessel vasculitis and development of severe Sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome.
    Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Ueno D; Yamasaki T; Itoh T; Yokozaki H; Katayama Y
    Eur J Haematol; 2014 Apr; 92(4):362-4. PubMed ID: 24341928
    [No Abstract]   [Full Text] [Related]  

  • 20. Azacitidine-induced cryptogenic organizing pneumonia: a case report and review of the literature.
    Alnimer Y; Salah S; Abuqayas B; Alrabi K
    J Med Case Rep; 2016 Jan; 10():15. PubMed ID: 26791087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.